top of page

Watch: HaemaLogiX Chief Scientific Officer Rosanne Dunn presenting the poster: ‘Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma’

Laptop On Tray

20 December 2022


UPDATE


HaemaLogiX Chief Scientific Officer Rosanne Dunn presented a poster at the 64TH American Society of Hematology(ASH) Annual Meeting & Exposition to be held in New Orleans, USA, on December 10 to 13, 2022.


View the poster.


View the presentation here.


From the abstract:


“These data show that KappaMab and LambdaMab have therapeutic potential in the treatment of myeloma patients, especially in the setting of relapsed refractory disease where the combination of high antigen density and restriction of the target antigen to the malignant subpopulation of plasma cells will confer valuable clinical benefit.”


Sartor, M., Gottlieb, DJ., and Dunn, R. (2022)

Novel Antigens LMA and KMA are Expressed on Malignant Bone Marrow Plasma Cells from Patients with Relapsed Refractory Multiple Myeloma and Plasma Cell Dyscrasias. Blood (2022) 140 (Supplement 1): 4211–4212.


View the full abstract here.

bottom of page